Should You Buy CONMED Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, CONMED Corporation (CNMD) scores a robust 8.5/10 on our 32-signal Quality of Company framework. At the current market price of $46.95 and a $1.4B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 6 of 12 CirclFi valuation models project upside for CONMED Corporation (CNMD) at $46.95 — the models are evenly split, with a Quality Score of 8.5/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for CONMED Corporation (CNMD) in 2026?
What Is the Bull Case vs the Bear Case for CONMED Corporation (CNMD)?
| Bull case — $85.46 target (+82.0%) | Bear case — $6.89 target (-85.3%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, CONMED Corporation's quality score of 8.5/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $6.89 (-85.3%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $85.46 (+82.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +167.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for CONMED Corporation's revenue and margin trajectory in the Medical Devices space. | Industry headwind: drug pricing legislation represents a meaningful risk for CONMED Corporation and its Medical Devices peers. |
How Does CNMD Compare to Its Medical Devices Peers?
Valuation data pages: INMD · XTNT · SNN · ZBH · EW · HAE · PROF · QDEL · HSCS · IRMD · PODD
Which Other Stocks Score Like CNMD on Quality?
Closest companies to CNMD’s Quality of Company score of 8.5/10, across all industries.
- APEI — American Public Education, Inc. (QOC 8.5) · analysis
- WDS — Woodside Energy Group Ltd (QOC 8.5) · analysis
- WDLF — Decentral Life, Inc. (QOC 8.5) · analysis
- IVDN — Innovative Designs, Inc. (QOC 8.5) · analysis
- AXON — Axon Enterprise, Inc. (QOC 8.5) · analysis
- RVRF — River Financial Corporation (QOC 8.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does CNMD Appear In?
So Is CONMED Corporation (CNMD) Worth Buying in 2026?
CONMED Corporation at $46.95 is a genuine coin-flip in our framework. The 6–6 bull-bear split across 12 models, +167.4% model spread, and median fair value of $47.17 (+0.5% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 8.5/10 adds some comfort to the mix.
These are quantitative model outputs, not investment recommendations. CONMED Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CNMD Stock?
Should I buy CNMD stock right now?
Based on CirclFi's multi-model analysis, 6 of 12 models see upside for CNMD at $46.95. The models are divided, which means the investment case depends heavily on your assumptions about CONMED Corporation's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in CONMED Corporation?
Key risks include: wide model disagreement (1140% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does CNMD compare to its competitors?
Among Medical Devices peers, CNMD holds a Quality Score of 8.5/10. Comparable companies include INMD (QOC 8.5), XTNT (QOC 8.4), SNN (QOC 8.6). The relative ranking helps investors identify whether CNMD offers better fundamental quality than alternatives in the same sector.
Is CNMD a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CNMD's Quality Score of 8.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy CNMD at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $6.89 to $85.46. At $46.95, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CNMD.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad